scholarly journals Five-year follow-up of new cases after a coeliac disease mass screening

2021 ◽  
pp. archdischild-2021-322755
Author(s):  
Olof Sandström ◽  
Fredrik Norström ◽  
Annelie Carlsson ◽  
Lotta Högberg ◽  
Maria van der Palz ◽  
...  
Keyword(s):  
Coeliac Disease ◽  
Mass Screening ◽  
Duodenal Mucosa ◽  
Population Based ◽  
Birth Cohorts ◽  
Disease Register ◽  
Screening Study ◽  
Screening Population

ObjectiveWe previously performed a population-based mass screening of coeliac disease in children aged 12 years in two birth cohorts resulting in 296 seropositive children, of whom 242 were diagnosed with coeliac disease after duodenal biopsies. In this follow-up study, we wanted to identify new cases in the screening population that tested negative—either converting from potential coeliac disease (seropositive but normal duodenal mucosa) or converting from seronegative at screening to diagnosed coeliac disease.MethodsAll seropositive children were invited to a follow-up appointment 5 years after the screening with renewed serological testing and recommended endoscopic investigation if seropositive. Seronegative children in the screening study (n=12 353) were linked to the National Swedish Childhood Coeliac Disease Register to find cases diagnosed in healthcare during the same period.ResultsIn total, 230 (77%) came to the follow-up appointment, including 34 of 39 with potential coeliac disease. Of these, 11 (32%) had converted to coeliac disease. One new case was found in the National Swedish Childhood Coeliac Disease Register who received the diagnosis through routine screening in children with type 1 diabetes.ConclusionsThere is a high risk of conversion to coeliac disease among those with potential disease. However, a negative screening test was associated with a very low risk for a clinical diagnosis within a follow-up period of 5 years.

scholarly journals Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies

2021 ◽  
Vol 11 (5) ◽  
Author(s):  
Sæmundur Rögnvaldsson ◽  
Thorvardur Jon Love ◽  
Sigrun Thorsteinsdottir ◽  
Elín Ruth Reed ◽  
Jón Þórir Óskarsson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Early Treatment ◽  
Monoclonal Gammopathy ◽  
Controlled Trial ◽  
Participation Rate ◽  
Population Based ◽  
Early Therapy ◽  
Screening Study ◽  
Undetermined Significance

AbstractMonoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy.

Blindness in a 25-Year Follow-up of a Population-Based Cohort of Danish Type 1 Diabetic Patients

Ophthalmology ◽  
2009 ◽  
Vol 116 (11) ◽  
pp. 2170-2174 ◽  
Author(s):  
Jakob Grauslund ◽  
Anders Green ◽  
Anne Katrin Sjølie
Keyword(s):  
Population Based ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients

Mortality risk remains higher in individuals with type 1 diabetes: A population-based cohort study (the Ayrshire diabetes follow-up cohort [ADOC])

2018 ◽  
Vol 20 (8) ◽  
pp. 1965-1971 ◽  
Author(s):  
Andrew Collier ◽  
Paul J. Connelly ◽  
Mario Hair ◽  
Lyall Cameron ◽  
Sujoy Ghosh ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cohort Study ◽  
Mortality Risk ◽  
Population Based

scholarly journals Cohort profile: the Funen Diabetes Database—a population-based cohort of patients with diabetes in Denmark

BMJ Open ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. e035492
Author(s):  
Kasper Adelborg ◽  
Péter Szentkúti ◽  
Jan Erik Henriksen ◽  
Reimar Wernich Thomsen ◽  
Lars Pedersen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Geographical Area ◽  
Population Based ◽  
Haemoglobin A1c ◽  
Patients With Diabetes

PurposeDetailed population-based data are essential to understanding the epidemiology of diabetes and its clinical course. This article describes the Funen Diabetes Database (FDDB). The purpose of the FDDB was to serve as a shared electronic medical record system for healthcare professionals treating patients with diabetes. The cohort can also be used for research.ParticipantsThe FDDB covers a geographical area of almost 500 000 Danish inhabitants. It currently includes 3691 patients with type 1 diabetes, 19 085 patients with type 2 diabetes, 292 patients with other types of diabetes and 5992 patients with an unknown type of diabetes. Patients have been continuously enrolled from general practitioners and endocrinology departments in the Funen area in Denmark since 2003. Patients undergo a clinical work-up at their first diabetes contact and during follow-up visits. The information collected includes type of diabetes contact, blood pressure, height, weight, lifestyle factors (smoking, exercise), laboratory records (eg, haemoglobin A1c and cholesterol levels), results from foot examinations (eg, pulse, cutaneous sensitivity and ankle brachial index), results from eye examinations (eg, degree of retinopathy assessed by retinal photo and eye examination), glucose-lowering drugs and diabetic complications.Findings to dateThe FDDB cohort was followed for a total of 212 234 person-years up to 2016. A cross-sectional study described the prevalence of diabetic retinopathy and its associated risk factors. The clinical outcomes of patients with type 1 diabetes, type 2 diabetes and latent autoimmune diabetes in adults have been assessed. Linkage to population-based medical registries with complete follow-up has enabled the collection of extensive continuous data on general practice contacts, diagnoses and procedures from hospital contacts, medication use and mortality.Future plansThe FDDB serves as a strong data resource that will be used in future studies of diabetes epidemiology with focus on occurrence, risk factors, treatment, complications and prognosis.

Screening for Neuroblastoma in Infants: Investigate or Implement?

PEDIATRICS ◽  
1990 ◽  
Vol 86 (5) ◽  
pp. 791-793
Author(s):  
MENDEL TUCHMAN ◽  
BERNARD LEMIEUX ◽  
WILLIAM G. WOODS
Keyword(s):  
North America ◽  
Mass Screening ◽  
Population Based ◽  
University Of Minnesota ◽  
Research Project ◽  
Screening Study ◽  
The Government ◽  
The University ◽  
Genetic Medicine ◽  
The Impact

The debate about whether to implement screening for neuroblastoma in North America is ongoing. Those in favor of implementing mass screening are quoting results from programs in Japan where the government has mandated neuroblastoma screening for infants.1-7 In North America, the Quebec Neuroblastoma Screening Study (QNS) has been established as a result of the collaboration between the Quebec Network for Genetic Medicine and the University of Minnesota. This controlled research project is studying the impact of screening infants for the preclinical detection of neuroblastoma on changes in population-based mortality caused by this tumor as well as on various biologic parameters and their relation to prognosis.8

scholarly journals Serum Markers of Refractoriness and Enteropathy-Associated T-Cell Lymphoma in Coeliac Disease

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2289
Author(s):  
Marco Vincenzo Lenti ◽  
Nicola Aronico ◽  
Paolo Giuffrida ◽  
Valentina Antoci ◽  
Giovanni Santacroce ◽  
...  
Keyword(s):  
Coeliac Disease ◽  
Serum Levels ◽  
Serum Markers ◽  
Upper Gastrointestinal Endoscopy ◽  
Significant Difference ◽  
Before And After ◽  
Work Up

The persistence or recurrence of symptoms in patients with coeliac disease (CD), despite a gluten-free diet (GFD), must prompt further work-up for excluding refractory CD (RCD). The aim of this study was to assess the accuracy of serum markers in predicting refractoriness in CD patients. This study included 72 patients affected by CD followed-up at our center, namely 49 uncomplicated CD before and after GFD and 23 RCD. Serum levels of chromogranin A (CgA) and β2-microglobuline were measured at baseline and at follow-up (median time of 13 months) in each group of patients. Cut-off points for each marker were estimated to differentiate RCD from uncomplicated CD patients. Serum levels of CgA and β2-microglobuline were significantly higher in patients with RCD compared to uncomplicated CD (p < 0.001), both at baseline and at follow-up, with no significant difference between RCD type 1 and type 2. The estimated cut-off point for CgA was 90.2 ng/mL (sensitivity 83%, specificity 100%), while for β2-microglobuline it was 696 mcg/L (sensitivity 100%, specificity of 100%). To conclude, CgA and β2-microglobuline could be useful serological markers of refractoriness in CD, with the ability to discriminate those patients who should undergo upper gastrointestinal endoscopy for making a definite diagnosis.

Sign in / Sign up

Export Citation Format

Share Document